How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,175 results for

Lymphadenopathy in HIV

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Clinical Findings of Pediatric HIV Infection in a Tertiary Center in Turkey Full Text available with Trip Pro

Clinical Findings of Pediatric HIV Infection in a Tertiary Center in Turkey Paediatric HIV infection is different from the adult type of disease in many ways, including transmission routes, clinical findings and treatment strategies.To evaluate clinical data of paediatric patients with HIV disease.Retrospective cross-sectional study.The charts of 22 paediatric patients diagnosed with HIV infection in our clinic during a 14 year period through 2001-2015 were retrospectively analysed. Clinical (...) data, laboratory findings, treatment modalities and outcomes were recorded.The mean age of diagnosis 61.9±49.2 months and the mean follow-up period was 60.3±37.5 months. Seven patients (31.8%) were foreigners and the most common transmission route was vertical transmission (n=16, 72.7%). The most common presenting symptom and the sign were history of recurrent upper respiratory tract infections (n=8, 36.4%) and lymphadenopathy (n=12, 54.5%), respectively. Recurrent pneumonia (n=6, 27.3%), prolonged

2017 Balkan medical journal

82. An Unusual Triad of Hemophagocytic Syndrome, Lymphoma and Tuberculosis in a Non-HIV Patient Full Text available with Trip Pro

An Unusual Triad of Hemophagocytic Syndrome, Lymphoma and Tuberculosis in a Non-HIV Patient BACKGROUND Lymphoma complicated with hemophagocytic syndrome and tuberculosis has been rarely reported. The clinical and radiological presentation of these potentially fatal conditions can be easily confused and there is a potential for misdiagnosis. CASE REPORT We present a 58-year-old Hispanic female who was admitted to the hospital with dizziness and fever. Her initial admission diagnosis was severe (...) sepsis secondary to community acquired pneumonia. She was started on intravenous antibiotics. Due to mediastinal lymphadenopathy, lymphoma was considered as a differential diagnosis for which she underwent bronchoscopy and endobronchial ultrasound-guided sampling of her mediastinal lymph nodes. Lymph node aspirate was suggestive of lymphoma. Initial cultures were negative. Her clinical course was complicated with respiratory failure, cytopenia, and rapidly progressive cervical lymphadenopathy

2017 The American journal of case reports

83. Small bowel obstruction due to mesenteric abscess caused by Mycobacterium avium complex in an HIV patient: a case report and literature review Full Text available with Trip Pro

Small bowel obstruction due to mesenteric abscess caused by Mycobacterium avium complex in an HIV patient: a case report and literature review Small bowel obstruction in HIV patients is reportedly caused by inflammatory pseudotumor, Kaposi's sarcoma, cryptococcal lymphadenopathy and intestinal tuberculosis. The incidence of Mycobacterium avium complex (MAC) infection in HIV patients is 3% for CD4 cell count of 100-199 /mm3. MAC causing small bowel obstruction is rarely reported (...) in the literature. We report a rare case of MAC causing mesenteric abscess with small bowel obstruction in a HIV patient with a CD4 cell count of 144 /mm3. Patient was a 35-year-old HIV-positive male on highly active antiretroviral therapy who presented with partial small bowel obstruction secondary to mesenteric abscess. He underwent operative intervention for drainage with cultures growing MAC.

2017 Journal of surgical case reports

84. Role of Autophagy in HIV-1 Matrix Protein p17-Driven Lymphangiogenesis Full Text available with Trip Pro

lymphangiogenesis occurs in the lymph nodes of HIV+ patients under successful cART. The HIV-1 matrix protein p17 is detected in blood and accumulates in the lymph node germinal centers even in the absence of virus replication. Several findings suggest a key role for p17 as a microenvironmental factor capable of promoting lymphangiogenesis. Here, we show that p17 promotes lymphangiogenesis of human lymph node-derived lymphatic endothelial cells (LN-LECs). The lymphangiogenic activity of p17 is sustained (...) activity of p17. Here, we show that the p17 lymphangiogenic activity occurs on human lymph node-derived lymphatic endothelial cells (LN-LECs) under stress conditions only and relies entirely on activation of an autophagy-based pathway. In fact, induction of autophagy by p17 promotes lymphangiogenesis, whereas pharmacological and genetic inhibition of autophagy inhibits p17-triggered lymphangiogenesis. Similarly, the vasculogenic activity of p17 was totally inhibited in autophagy-incompetent mice. Our

2017 Journal of virology

85. Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy Full Text available with Trip Pro

Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy We report the first case to our knowledge of a patient with relapsed/refractory classical hodgkin lymphoma and liver failure with encephalopathy along with human immunodeficiency virus/acquired immunodeficiency syndrome infection, successfully treated with nivolumab without major side effects and encouraging prolonged disease control.In December 2015 (...) doses), restaging (computerized tomography scans of neck, chest, abdomen, pelvis) done on May 2016 showed resolution of hepatosplenomegaly with two residual small hepatic lesions, heterogeneous spleen with no splenic lesions, and stable non-enlarged retroperitoneal lymph nodes without intraabdominal lymphadenopathy; consistent with partial response.We report a case of a patient with human immunodeficiency virus/acquired immunodeficiency syndrome -related relapsed/refractory classical Hodgkin

2017 Journal for immunotherapy of cancer

86. Comparative genomics of Cryptococcus neoformans var. grubii associated with meningitis in HIV infected and uninfected patients in Vietnam Full Text available with Trip Pro

by lineage and found HIV infected patients with cryptococcal meningitis caused by ST5 organisms were significantly more likely to have lymphadenopathy (11% vs. 4%, p = 0.05 Fisher's exact test) and higher blood lymphocyte count (median 0.76 versus 0.55 X109 cells/L, p = 0.001, Kruskal-Wallis test). Furthermore, survivors of ST5 infections had evidence of worse disability outcomes at 70 days (72.7% (40/55) in ST5 infections versus 57.1% (52/91) non-ST5 infections (OR 2.11, 95%CI 1.01 to 4.41), p = 0.046 (...) Comparative genomics of Cryptococcus neoformans var. grubii associated with meningitis in HIV infected and uninfected patients in Vietnam The vast burden of cryptococcal meningitis occurs in immunosuppressed patients, driven by HIV, and is caused by Cryptococcus neoformans var. grubii. We previously reported cryptococcal meningitis in Vietnam arising atypically in HIV uninfected, apparently immunocompetent patients, caused by a single amplified fragment length polymorphism (AFLP) cluster of C

2017 PLoS neglected tropical diseases

87. MMF for HIV Reservoir Reduction

cells. MMF will eliminate detectable measures of the HIV reservoir, including by cell-associated DNA/mRNA and quantitative viral outgrowth. MMF will not decrease the humoral immune response to routine annual influenza vaccination. Condition or disease Intervention/treatment Phase Human Immunodeficiency Virus I Infection Drug: Mycophenolate Mofetil 500Mg Tab Phase 2 Detailed Description: This is an open-label, randomized pilot trial to determine whether MMF given over 22 months meaningfully decreases (...) Antiretroviral treatment Mycophenolate mofetil Cure Latency Reservoir CD4 T cell Anti-proliferation Additional relevant MeSH terms: Layout table for MeSH terms Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Mycophenolic Acid Antibiotics, Antineoplastic Antineoplastic Agents

2017 Clinical Trials

88. Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY

activation, which lead to immune deterioration and premature aging of HIV-1-infected subjects, including metabolic disturbances, cardiovascular diseases, cognitive disorders and HIV-associated cancers. Persistence of residual HIV-1 replication in the presence of ART has been associated to incomplete HIV-1 suppression in gut lymphatic tissues due to suboptimal tissular penetration of PI/s or NNRTIs. In previous work in our institute, the investigators have observed that HIV-1 infection is independently (...) Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search

2017 Clinical Trials

89. Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Description Go to Brief Summary: This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (HIV)-positive stage II-IV diffuse large B-cell lymphomas. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere (...) IHC. Percentage of participants who receive two or more cycles of combination chemotherapy, and are able to continue on a minimum dose level of cyclophosphamide of -1 and above after dose adjustments [ Time Frame: Up to 5 years ] Hematologic toxicities will be calculated. Average number of days per cycle participants are able to stay on planned dose of ibrutinib [ Time Frame: Up to 5 years ] Average number of days will be calculated. Changes in the levels of human immunodeficiency virus (HIV)-1

2017 Clinical Trials

90. Development and validation of a risk score to assist screening for acute HIV-1 infection among men who have sex with men. Full Text available with Trip Pro

Development and validation of a risk score to assist screening for acute HIV-1 infection among men who have sex with men. Early treatment of acute HIV-1 infection (AHI) is beneficial for patients and could reduce onward transmission. However, guidelines on whom to test for AHI with HIV-1 RNA testing are lacking.A risk score for possible AHI based on literature and expert opinion - including symptoms associated with AHI and early HIV-1 - was evaluated using data from the Amsterdam Cohort Studies (...) among men who have sex with men (MSM). Subsequently, we optimized the risk score by constructing two multivariable logistic regression models: one including only symptoms and one combining symptoms with known risk factors for HIV-1 seroconversion, using generalized estimating equations. Several risk scores were generated from these models and the optimal risk score was validated using data from the Multicenter AIDS Cohort Study.Using data from 1562 MSM with 175 HIV-1 seroconversion visits and 17,271

2017 BMC Infectious Diseases

91. HIV-associated malignancies

December 2013). 5 Bower M, Collins S, Cottrill C et al. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 2008; 9: 336–388. 6 Curtis JR, Bennett CL, Horner RD et al. Variations in intensive care unit utilization for patients with human immunode?ciency virus-related Pneumocystis carinii pneumonia: importance of hospital characteristics and geographic location. Crit Care Med 1998; 26: 668–675. 7 Handford CD, Rackal JM, Tynan A-M et al. The association of hospital, clinic (...) , King’s College Hospital, London Dr Sylvia Montoto Consultant in Haemato-oncology, St Bartholomew’s Hospital, Barts Health NHS Trust, London Dr Mark Nelson Consultant Physician, Chelsea and Westminster Hospital NHS Foundation Trust, London, and Adjunct Professor and Reader in Human Immunode?ciency Virology, Imperial College London Dr Tom Newsom-Davis Consultant Medical Oncologist, Chelsea and Westminster Hospital NHS Foundation Trust, London Dr Chloe Orkin Consultant Physician and Lead for HIV

2014 British HIV Association

92. Effect of Wuchereria bancrofti infection on HIV incidence in southwest Tanzania: a prospective cohort study. (Abstract)

Effect of Wuchereria bancrofti infection on HIV incidence in southwest Tanzania: a prospective cohort study. The past decades have seen an ongoing controversial debate about whether the immune activation induced by helminths has an effect on the susceptibility of individuals to HIV. In view of this, we assessed the effect of lymphatic filariasis, a chronic helminth disease elicited by Wuchereria bancrofti, on HIV incidence in southwest Tanzania.In this population-based cohort study, we enrolled (...) a geographically stratified randomly chosen sample of about 10% of the households in nine distinct sites in southwest Tanzania. All household members present were followed up and tested for HIV and circulating filarial antigen, an indicator of W bancrofti adult worm burden. Our main outcome of interest was HIV incidence in participants with or without lymphatic filariasis.Between May 29, 2006, and June 16, 2011, we enrolled 4283 households with roughly 18 000 participants. Of these, 2699 individuals from Kyela

2016 Lancet

93. Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

: March 4, 2015 Last Update Posted : December 27, 2018 Sponsor: Fred Hutchinson Cancer Research Center Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Fred Hutchinson Cancer Research Center Study Details Study Description Go to Brief Summary: This clinical trial studies gene-modified, human immunodeficiency virus (HIV)-protected stem cell transplant in treating patients with HIV-associated lymphoma. Stem cells, or cells which help form blood, are collected (...) , 2018 Last Verified: December 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma HIV Infections Lymphoma, Non-Hodgkin Hodgkin Disease Lymphoma, AIDS-Related Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted

2015 Clinical Trials

94. Lymphoma in HIV

, HIV related Lymphoma , AIDS related Lymphoma From Related Chapters II. Types: Hodgkin's Lymphoma mildly increased in HIV Course may be more aggressive in HIV May have less complete response to III. Types: Non-Hodgkin's Lymphoma Occurs when median CD4=200 cells Rapid tumor growth with extranodal disease Non-lymphatic sites: , GI, , Usually widespread (stage 4) at time of diagnosis Poor prognosis in patients with advanced HIV Median duration of survival is 3-6 months Associated with EBV viral gene (...) -cell, and Hodgkin lymphomas. The prognosis is closely related to the severity of immunodeficiency. Concepts Neoplastic Process ( T191 ) MSH English AIDS Associated Lymphoma , AIDS related lymphoma , AIDS-Associated Lymphoma , AIDS-Associated Lymphomas , AIDS-Related Lymphoma , AIDS-Related Lymphomas , Lymphoma, AIDS Related , Lymphoma, AIDS-Associated , Lymphomas, AIDS-Associated , Lymphomas, AIDS-Related , HIV Related Lymphoma , HIV-Related Lymphoma , HIV-Related Lymphomas , Lymphoma, AIDS

2018 FP Notebook

95. Causes of cervical lymphadenopathy at Kamuzu Central Hospital Full Text available with Trip Pro

Causes of cervical lymphadenopathy at Kamuzu Central Hospital Description of pathologic causes of cervical lymphadenopathy at Kamuzu Central Hospital.The evaluation of cervical lymphadenopathy is a common diagnostic challenge facing clinicians. Previously at Kamuzu Central Hospital (KCH) tuberculosis (TB) was reported to be the most common cause of cervical lymphadenopathy However, no recent study has assessed this common diagnostic challenge in Malawi, particularly since the beginning (...) of the HIV epidemic and the subsequent scale-up of antiretroviral therapy.We conducted a cross-sectional study of all cervical lymph node specimens from the KCH pathology laboratory between 1 July 2011 and 28 February 2013 and describe patient age, gender, and pathologic diagnoses.Our search of the KCH pathology database yielded 179 cases. Of these, 143 (77%) were histologic specimens (open biopsy or core needle samples) while 34 (23%) were cytology specimens. The age range was from 0 to 76 years

2014 Malawi Medical Journal

96. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Full Text available with Trip Pro

defects 63%, pulmonary alveolar proteinosis 18%, pulmonary arterial hypertension 9%), dermatologic (warts 53%, panniculitis 30%), neoplastic (human papillomavirus+ tumors 35%, Epstein-Barr virus+ tumors 4%), vascular/lymphatic (venous thrombosis 25%, lymphedema 11%), sensorineural hearing loss 76%, miscarriage 33%, and hypothyroidism 14%. Viral infections and lymphedema were more common in individuals with null mutations (P = .038 and P = .006, respectively). Monocytopenia, B, NK, and CD4 (...) lymphocytopenia correlated with the presence of disease (P < .001). GATA2 deficiency unites susceptibility to MDS/AML, immunodeficiency, pulmonary disease, and vascular/lymphatic dysfunction. Early genetic diagnosis is critical to direct clinical management, preventive care, and family screening.

2014 Blood

97. MKSAP: 30-year-old woman with HIV infection

scheduled childhood immunizations. On physical examination, vital signs are normal. She has shotty cervical lymphadenopathy, but the examination is otherwise unremarkable. Laboratory studies: Absolute CD4 cell count 461/µL HIV viral load 44,874 copies/mL Hepatitis A IgG antibody Negative Hepatitis B surface antibody Positive Hepatitis B surface antigen Negative Hepatitis C antibody Negative Which of the following immunizations should this patient receive today? A. Hepatitis A vaccine B. Hepatitis B (...) vaccine C. Human papillomavirus vaccine D. Pneumococcal conjugate vaccine E. Pneumococcal polysaccharide vaccine MKSAP Answer and Critique The correct answer is D. Pneumococcal conjugate vaccine. This patient should receive the 13-valent pneumococcal conjugate vaccine (PCV13) now. Vaccination against Streptococcus pneumoniae is indicated in all persons with HIV infection because of the increased risk of invasive pneumococcal disease. Immunocompromised persons, including those with HIV, should receive

2018 KevinMD blog

98. Lymphadenopathy (Follow-up)

Lymphadenopathy (Follow-up) Lymphadenopathy Follow-up: Further Outpatient Care, Further Inpatient Care, Inpatient & Outpatient Medications Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTU2MzQwLWZvbGxvd3Vw (...) processing > Lymphadenopathy Follow-up Updated: Feb 01, 2018 Author: Vikramjit S Kanwar, MBBS, MBA, MRCP(UK), FAAP; Chief Editor: Russell W Steele, MD Share Email Print Feedback Close Sections Sections Lymphadenopathy Follow-up Further Outpatient Care Further outpatient treatment depends on establishing a diagnosis and determining management of that diagnosis. Next: Further Inpatient Care Additional inpatient treatment depends on establishing the diagnosis and determining management based

2014 eMedicine Pediatrics

99. Lymphadenopathy (Treatment)

Oncol . 2006 Oct-Nov. 23(7):549-61. . Yaris N, Cakir M, Sozen E, Cobanoglu U. Analysis of children with peripheral lymphadenopathy. Clin Pediatr (Phila) . 2006 Jul. 45(6):544-9. . Gray DM, Zar H, Cotton M. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Cochrane Database Syst Rev . 2009 Jan 21. CD006418. . Leung AK, Davies HD. Cervical lymphadenitis: etiology, diagnosis, and management. Curr Infect Dis Rep . 2009 May. 11(3):183-9. . Lindeboom JA (...) Lymphadenopathy (Treatment) Lymphadenopathy Treatment & Management: Medical Care, Surgical Care, Consultations Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTU2MzQwLXRyZWF0bWVudA== processing > Lymphadenopathy

2014 eMedicine Pediatrics

100. Lymphadenopathy (Overview)

immunodeficiency virus (HIV), malignancies, and autoimmune diseases, are less common causes of adenopathy. International Infections that are rarely observed in the United States, such as , typhoid fever, , , , , and fungal infections, are common causes of lymphadenopathy in developing nations. [ ] HIV infections must be strongly considered in areas of high incidence. Mortality/Morbidity In the United States, mortality and serious morbidity caused by adenopathy are unusual given the common infectious etiologies (...) . Malignancies, such as leukemia, lymphomas, and , are the primary causes of mortality in the United States. [ ] Significant morbidity and mortality are also associated with autoimmune disorders (eg, , ), , and storage diseases. HIV is an uncommon cause of adenopathy in the United States, but its associated mortality requires consideration. Race Race is not a factor in most lymphadenopathy. Rare causes may be associated with particular ethnic groups (eg, sarcoidosis in Africans, Kikuchi-Fujimoto disease

2014 eMedicine Pediatrics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>